cAMP signaling pathway in antigen-presenting cells (cAMP signaling in APCs)

The cAMP signaling pathway in antigen-presenting cells (APCs), including dendritic cells and macrophages, is a critical regulatory axis that modulates immune activation and tolerance (Serezani et al., 2008, PubMed: 18403781). Intracellular levels of cyclic adenosine monophosphate (cAMP) are controlled by the opposing actions of adenylate cyclases, which synthesize cAMP, and phosphodiesterases (PDEs), particularly the PDE4 isoform, which degrade it (Maurice et al., 2014, PubMed: 24385249). Elevated cAMP levels in APCs generally exert immunosuppressive effects by activating Protein Kinase A (PKA) and EPAC, leading to the inhibition of pro-inflammatory cytokines like TNF-alpha and IL-12, while promoting anti-inflammatory IL-10 production (Serezani et al., 2008; Schafer, 2012, PubMed: 22579807). This pathway also impairs APC maturation and the expression of co-stimulatory molecules such as CD80 and CD86, thereby dampening T-cell activation (Kambayashi et al., 2001, PubMed: 11564776). Pharmacological agents like the PDE4 inhibitor apremilast exploit this mechanism to treat autoimmune and inflammatory conditions by maintaining higher cAMP levels to suppress chronic inflammation (Schafer, 2012; Raker et al., 2016, PubMed: 27148255).

Other names

Cyclic AMP signaling in APCscAMP-mediated immune regulationAdenosine 3',5'-cyclic monophosphate signaling in dendritic cells

Modulation of intracellular cAMP levels via activation of adenylate cyclases or inhibition of phosphodiesterases (primarily PDE4) to suppress pro-inflammatory cytokine production and APC maturation.